ArticlePloS one2016
Shape-Related Toxicity of Titanium Dioxide Nanofibres.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 72 citations in OpenAlex.
- Detection of cancer epigenetic alterations in a pilot cohort of workers exposed to TiOFrontiers in toxicology · 2026Article
- Toxicological impacts of microplastic fibers: A review assessing risk to human and aquatic health.Environmental research · 2026Review
- Experimental assessment of damage and microplastic release during cyclic loading of clear aligners.PloS one · 2025Article
- Hazard assessment of nanomaterials: how to meet the requirements for (next generation) risk assessment.Particle and fibre toxicology · 2024Article
- In Vitro Safety Assessment of In-House Synthesized Titanium Dioxide Nanoparticles: Impact of Washing and Temperature Conditions.International journal of molecular sciences · 2023Article
- Effect of Silica Microparticles on Interactions in Mono- and Multicomponent Membranes.International journal of molecular sciences · 2022Article
- Evaluating the Use of TiOInternational journal of nanomedicine · 2022Article
- Emissions and exposures of graphene nanomaterials, titanium dioxide nanofibers, and nanoparticles during down-stream industrial handling.Journal of exposure science & environmental epidemiology · 2021Article
- Smart Electrospun Hybrid Nanofibers Functionalized with Ligand-Free Titanium Nitride (TiN) Nanoparticles for Tissue Engineering.Nanomaterials (Basel, Switzerland) · 2021Article
- Two-Step Triethylamine-Based Synthesis of MgO Nanoparticles and Their Antibacterial Effect against Pathogenic Bacteria.Nanomaterials (Basel, Switzerland) · 2021Article
- Graphdiyne-modified TiONature communications · 2020Article
- Titanium Dioxide Nanoparticles in Food and Personal Care Products-What Do We Know about Their Safety?Nanomaterials (Basel, Switzerland) · 2020Review
- Insights into Theranostic Properties of Titanium Dioxide for Nanomedicine.Nano-micro letters · 2020Review
- Visible-Light Active Titanium Dioxide Nanomaterials with Bactericidal Properties.Nanomaterials (Basel, Switzerland) · 2020Review
- Toxicity of nanoparticles_ challenges and opportunities.Applied microscopy · 2019Review
- Biological monitoring of workers exposed to engineered nanomaterials.Toxicology letters · 2018Review
- The Secretory Response of Rat Peritoneal Mast Cells on Exposure to Mineral Fibers.International journal of environmental research and public health · 2018Article
- Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer.Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Titanium dioxide (TiO2) nanofibres are a novel fibrous nanomaterial with increasing applications in a variety of fields. While the biological effects of TiO2 nanoparticles have been extensively studied, the toxicological characterization of TiO2 nanofibres is far from being complete. In this study, we evaluated the toxicity of commercially available anatase TiO2 nanofibres using TiO2 nanoparticles (NP) and crocidolite asbestos as non-fibrous or fibrous benchmark materials. The evaluated endpoints were cell viability, haemolysis, macrophage activation, trans-epithelial electrical resistance (an indicator of the epithelial barrier competence), ROS production and oxidative stress as well as the morphology of exposed cells. The results showed that TiO2 nanofibres caused a cell-specific, dose-dependent decrease of cell viability, with larger effects on alveolar epithelial cells than on macrophages. The observed effects were comparable to those of crocidolite, while TiO2 NP did not decrease cell viability. TiO2 nanofibres were also found endowed with a marked haemolytic activity, at levels significantly higher than those observed with TiO2 nanoparticles or crocidolite. Moreover, TiO2 nanofibres and crocidolite, but not TiO2 nanoparticles, caused a significant decrease of the trans-epithelial electrical resistance of airway cell monolayers. SEM images demonstrated that the interaction with nanofibres and crocidolite caused cell shape perturbation with the longest fibres incompletely or not phagocytosed. The expression of several pro-inflammatory markers, such as NO production and the induction of Nos2 and Ptgs2, was significantly increased by TiO2 nanofibres, as well as by TiO2 nanoparticles and crocidolite. This study indicates that TiO2 nanofibres had significant toxic effects and, for most endpoints with the exception of pro-inflammatory changes, are more bio-active than TiO2 nanoparticles, showing the relevance of shape in determining the toxicity of nanomaterials. Given that several toxic effects of TiO2 nanofibres appear comparable to those observed with crocidolite, the possibility that they exert length dependent toxicity in vivo seems worthy of further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.